Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

This study has been completed.
Sponsor:
Information provided by:
Clinical Trial Agency of HIV Study Group
ClinicalTrials.gov Identifier:
NCT00256828
First received: November 21, 2005
Last updated: October 15, 2007
Last verified: November 2005